Since the original work by Charles Huggins in 1941 on the effects of ADT on progression to lethal disease, the emergence of castration resistance in patients with prostate cancer has reinforced the need for understanding actionable drivers of prostate cancer progression beyond AR, its ligands, and downstream targets. Here, AR is linked to prostate carcinoma.